2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
13
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
pegfilgrastim
30
Filgrastim
29
Cyclophosphamide
10
pegylated granulocyte colony-stimulating factor
8
Docetaxel
8
Etoposide
7
Cytarabine
7
Ciprofloxacin
6
Cefepime
6
Vancomycin
5
Leucovorin
5
Fluorouracil
5
eflapegrastim
4
Granulocyte Colony-Stimulating Factor
4
Doxorubicin
4
Peripheral Blood Stem Cell Transplantation
3
Mitoxantrone
3
Methotrexate
3
Levofloxacin
3
Irinotecan
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Caspofungin
3
Carboplatin
3
Amikacin
3
trifluridine tipiracil drug combination
2
plerixafor
2
liposomal amphotericin B
2
Vincristine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neutropenia
×
Sodium Chloride
×
Clear all
NCT01619423
2018-07-06
PLIANT
Egetis Therapeutics
Phase 1/2
Completed
186 enrolled
12 charts